Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07408609 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

114

Enrollment

OTHER

Sponsor class

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Low Dose Radiotherapy Combined with Tislelizumab and Chemotherapy
DRUG: Chemotherapeutic Agent
DEVICE: low-dose radiotherapy

Sponsor

Jiangsu Cancer Institute & Hospital